Pimagedine: a novel therapy for diabetic nephropathy

Bibliography

• THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. I Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. (1995) 47:1703–1720.
   PubMed Web of Science ®Google Scholar
• COLWELL JA: Intensive insulin therapy inType II diabetes: rationale and collaborative clinical trial results. Diabetes (1996) 45 (Suppl. 3):S87–S90.
   Google Scholar
• Tight blood pressure control, and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ(1998) 317:703–713.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl. J. Med. (1993) 329:1456–1462.
   PubMed Web of Science ®Google Scholar
• THE MICROALBUMINURIA CAPTOPRIL STUDY GROUP: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia (1996) 39:587–593.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. J. Med. (2001) #20;345: 851–860.
   Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: Effect of Irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl. J. Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• PEDRINI MT, LEVEY AS, LAU J, CHALMERS TC, WANG PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann. Intern. Med. (1996) 124:627–632.
   PubMed Web of Science ®Google Scholar
• USRDS 1999 ANNUAL DATA REPORT: Incidence and prevalence of ESRD. Am. I Kid. Dis. (1999) 34:S40–S50.
   Google Scholar
• ANIMESH C, SANJAY S, MARK PJ, ARUNI B, SATISH S: Active site modification of aldose reductase by nitric oxide donors. Biochim. Biophys. Acta (1997) 134:217–222.
   Google Scholar
• KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859–866.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the role of PKC in diabetic complications.
   Google Scholar
• SOULIS-LIPAROTA T, COOPER ME, DUNLOP M, JERUMS G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia (1995) 38:387–394.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN EA: Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care (1999) 22 (Suppl. 2):B65–B71.
   Google Scholar
• NAKAMURA J, KATO K, HAMADA Yet al.: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes (1999) 48:2090–2095.
   Google Scholar
• AIELLO LP, BURSELL SE, CLERMONT A et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivoand suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 46:1473–1480.
   PubMed Web of Science ®Google Scholar
• KOYA D, HANEDA M, NAKAGAWA H et al.: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model Type 2 diabetes. FASEB (2000) 14:439–447.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M: Nonenzymatic glycosylation of macromolecules. Prospects of pharmacologic modulation. [Review] [48 refs]. Diabetes (1992) 41\(Suppl. 2):57–60.
   Google Scholar
• BROWNLEE M: Lilly Lecture 1993. Glycation and diabetic complications. Diabetes (1994) 43:836–841.
   Google Scholar
• FU MX, REQUENA JR, JENKINS AJ, LYONS TJ, BAYNES JW, THORPE SR: The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions.j Biol. Chem. (1996) 271:9982–9986.
   PubMed Web of Science ®Google Scholar
• O'BRIEN J, MORRISSEY PA: Nutritionaland toxicological aspects of the Maillard browning reaction in foods. Grit. Rev Food Sci. Nutr. (1989) 28:211–248.
   Google Scholar
• KOSCHINSKY T, HE CJ, MITSUHASHI T et al.: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. (1997) 94:6474–6479.
   PubMed Web of Science ®Google Scholar
• GLOMB MA, PFAHLER C: Amides are novel protein modifications formed by physiological sugars. Biol. Chem. (2001) 276:41638–41647.
   Web of Science ®Google Scholar
• SENSI M, PRICCI F, ANDREANI D, DI M: Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res. (1991) 16:1–9.
   PubMedGoogle Scholar
• WAGNER Z, WITTMANN I, MAZAK let al.: N(epsilon)-(carboxymethAlysine levels in patients with Type 2 diabetes: role of renal function. Jim. .1 Kidney Dis. (2001) 38:785–791.
   Google Scholar
• •Human study showing increased serum fluorescent AGE and CIVIL levels, and decreased urinary CIVIL excretion rates in diabetes Type 2 patients with renal impairment.
   Google Scholar
• YAMADA K, MIYAHARA Y, HAMAGUCHI K et al.: Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin. NephroL (1994) 42:354–361.
   PubMed Web of Science ®Google Scholar
• MAKITA Z, BUCALA R, RAYFIELD EJ et al.: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet (1994) 343:1519–1522.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl. Med. (1988) #19;318: 1315–1321.
   Google Scholar
• •Classic seminar discussing the key role of AGE in diabetic complications.
   Google Scholar
• BROWNLEE M, VLASSARA H, KOONEY A, ULRICH P, CERAMI A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 232:1629–1632.
   PubMed Web of Science ®Google Scholar
• FOOTE EF, LOOK ZM, GILES P, KEANE WE HALSTENSON CE: The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. Ain..1. Kidney Dis. (1995) 25:420–425.
   Google Scholar
• •Human study of the pharmacokinetic of PG in patients with ESRD on haemodialysis with suggestion of dosing recommendations of the drug.
   Google Scholar
• KHATAMI M, SULDAN Z, DAVID I, LI W, ROCKEY JH: Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. Life Sci. (1988) 43:1725–1731.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN D, BROWNLEE M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes (1992) 41:26–29.
   PubMed Web of Science ®Google Scholar
• SCULER W, DER HEMMUNG Z: Diamino oxydase (Histaminase). Experientia (1952) 8:230–232.
   PubMedGoogle Scholar
• CORBETT JA, TILTON RG, CHANG K etal.: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes (1992) 41:552–556.
   Google Scholar
• LASZLO F, EVANS SM, WHITTLE BJ: Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Ear: Phannacol (1995) 272:169–175.
   PubMed Web of Science ®Google Scholar
• LOPEZ-BELMONTE J, WHITTLE BJ: Aminoguanidine-provoked leukocyte adherence to rat mesenteric venules: role of constitutive nitric oxide synthase inhibition. Br.PhannacoL (1995) 116:2710–2714.
   Web of Science ®Google Scholar
• NILSSON BO: Biological effects of aminoguanidine: an update. (Review) (63 refs). Inflarnin. Res. (1999) 48:509–515.
   Google Scholar
• •Thorough review of the different biological effects of PG.
   Google Scholar
• STJERNBORG L, PERSSON L: Stabilization of S-adenosylmethionine decarboxylase by aminoguanidine. Biochein. Phannacol (1993) 45:1174–1176.
   PubMed Web of Science ®Google Scholar
• SVENSSON F, METT H, PERSSON L: CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Biochein. (1997) 322:297–302.
   PubMed Web of Science ®Google Scholar
• SAJITHLAL GB, CHITHRA P, CHANDRAKASAN G: Advanced glycation end products induce crosslinking of collagen in vitro. Biochlin. Biophys. Acta (1998) 1407:215–224.
   PubMed Web of Science ®Google Scholar
• SOULIS T, COOPER ME, SASTRA S et al: Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia (1997) 40:1141–1151.
   PubMed Web of Science ®Google Scholar
• •Study aiming to identify the mechanism by which PG exerts its renoprotective effect.
   Google Scholar
• KAPINS CEB, OKUYAMA P, SCHOR N, HIGA EMS: Evaluation of nitic oxide synthesis and the effect of aminoguanidine on diabetic nephropathy. I Jim. Soc. Nephrol (2000) 11:644A.
   Google Scholar
• SUGIMOTO H, SHIKATA K, WADA J, HORIUCHI S, MAKINO H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia (1999) 42:878–886.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. (Review) (63 refs). Am. Cardiol (1999) 83:25F–29F.
   Google Scholar
• REQUENA JR, FU MX, AHMED MU, JENKINS AJ, LYONS TJ, THORPE SR: Lipoxidation products as biomarkers of oxidative damage to proteins during lipid perwddation reactions. (Review) (28 refs). Nephrol Dial. Transplant. (1996) 11\(Suppl. 5):48–53.
   Google Scholar
• BAYNES JVV, THORPE SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. (Review) (91 refs). Diabetes (1999) 48:1–9.
   PubMed Web of Science ®Google Scholar
• OSICKA TM, YU Y, PANAGIOTOPOULOS S et al: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes (2000) 49:87–93.
   PubMed Web of Science ®Google Scholar
• BACH LA, DEAN R, YOUSSEF S, COOPER ME: Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol. Dial. Transplant. (2000) 15:347–354.
   PubMed Web of Science ®Google Scholar
• KELLY DJ, GILBERT RE, COX AJ, SOULIS T, JERUMS G, COOPER ME: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. I Am. Soc. Nephrol. (2001) 12:2098–2107.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, COTTER MA: Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies. (Review) (161 refs). Diabet. Med. (1993) 10:593–605.
   PubMed Web of Science ®Google Scholar
• VINIK Al: Diabetic neuropathy: pathogenesis and therapy. (Review) (75 refs). Am. Med. (1999) 107:17S–26S.
   Google Scholar
• COOPER ME, BONNET F, OLDFIELD M, JANDELEIT-DAHM K: Mechanisms of diabetic vasculopathy: an overview. Am. Hypertens. (2001) 14:475–486.
   PubMed Web of Science ®Google Scholar
• HARDING JJ: Pharmacological treatment strategies in age-related cataracts. (Review) (115 refs). Drugs Aging (1992) 2:287–300.
   PubMed Web of Science ®Google Scholar
• COOPER ME, GILBERT RE, JERUMS G: Diabetic vascular complications. Clin. Exp. Pharmacol Physiol. (1997) 24:770–775.
   PubMed Web of Science ®Google Scholar
• BUCALA R: What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?. (Review) (42 refs). Diabetes Res. Clin. Prac. (1996) 30 (Suppl.):123–130.
   Google Scholar
• YAMAUCHI A, TAKEI I, MAKITA Z et al: Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res. Clin. Prac. (1997) 34:127–133.
   PubMed Web of Science ®Google Scholar
• SOULIS-LIPAROTA T, COOPER M, PAPAZOGLOU D, CLARKE B, JERUMS G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes (1991) 40:1328–1334.
   PubMed Web of Science ®Google Scholar
• ITAKURA M, YOSHIKAWA H, BANNAI C et al.: Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci. (1991) 49:889–897.
   PubMed Web of Science ®Google Scholar
• ELLIS EN, GOOD BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism (1991) 40:1016–1019.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN D, BROWNLEE M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia (1992) 35:96–97.
   PubMed Web of Science ®Google Scholar
• VLASSARA H, STRIKER LJ, TEICHBERG S, FUH H, LI YM, STEFFES M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Nati Acad. Sri. (1994) 91:11704–11708.
   PubMed Web of Science ®Google Scholar
• OXLUND H, ANDREASSEN TT: Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. Diabetologia (1992) 35:19–25.
   PubMed Web of Science ®Google Scholar
• YOUSSEF S, NGUYEN DT, SOULIS T, PANAGIOTOPOULOS S, JERUMS G, COOPER ME: Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. (1999) 55:907–916.
   PubMed Web of Science ®Google Scholar
• SOULIS T, COOPER ME, VRANES D, BUCALA R, JERUMS G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. (1996) 50:627–634.
   PubMed Web of Science ®Google Scholar
• ALTEON INC.: Pimagedine hydrochloride (aminoguanidine hydrochloride). Unpublished
   Google Scholar
• APPEL G, BOLTON WK, FREEDMAN B, WUERTH J-P, CARTWRIGHT K: Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with Type I diabetes mellitus. J. Arn. Soc. Nephrol (1999) 10:153A.
   Google Scholar
• WHITTIER F, SPINOWITZ B, WUERTH J-P, CARTWRIGHT K: Pimagedine (PG) safety profile in patients with Type I diabetes mellitus (DM). J. Am. Soc. Nephrol (1999) 10:184A.
   PubMed Web of Science ®Google Scholar
• BOLTON WK, CATTRAN DC, WILLIAMS ME et al.: Randomized trial of advanced glycosylation end product formation in patients with diabetic nephropathy. Submitted (2001).
   Google Scholar
• FREEDMAN BI, WUERTH J-P, CARTWRIGHT K et al.: Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control. Clin. Trials(1999) 20:493–510.
   PubMedGoogle Scholar
• •Prospective well-designed clinical study of PG in overt Type 2 diabetic nephropathy.
   Google Scholar
• HRUBY ZW, KOSCIELNIAK K, FILIPOWSKI H: An AGE-inhibitor aminoguanidine is more effective than enalapril in preventing glomerulosclerosis in experimental diabetes. Am. Soc. Nephrol (1999) 10:284A.
   Google Scholar
• DAVIS BJ, FORBES JM, JERUMS G, COOPER ME, ALLEN TJ: Does combined blockade of the RAS and AGE formation confer superior renoprotection in a hypertensive model of diabetic nephropathy? Am. Soc. Nephrol (2001) 12:833A.
   Google Scholar
• RAHBAR S, NATARAJAN R, YERNENI K, SCOTT S, GONZALES N, NADLER JL: Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta (2000) 301:65–77.
   PubMed Web of Science ®Google Scholar
• KOCHAKIAN M, MANJULA BN, EGAN JJ: Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes (1996) 45:1694–1700.
   PubMed Web of Science ®Google Scholar
• SOULIS T, SASTRA S, THALLAS V et al.: A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia (1999) 42:472–479.
   PubMed Web of Science ®Google Scholar
• FORBES JM, SOULIS T, THALLAS V et al.: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia (2001) 44:108–114.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, MAKITA Z, ISHIKAWA Set al.: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes (1997) 46:895–899.
   Google Scholar
• TSUCHIDA K, MAKITA Z, YAMAGISHI S et al.: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia (1999) 42:579–588.
   PubMed Web of Science ®Google Scholar
• VASAN S, ZHANG X, ZHANG X et al.: Anagent cleaving glucose-derived protein crosslinks M vitro and in vivo. Nature (1996): 275–278.
   PubMed Web of Science ®Google Scholar
• COOPER ME, THALLAS V, FORBES Jetal.: The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia (2000) 43:660–664.
   Google Scholar
• SCHWEDLER S, VERBEKE P, BAKALA H et al.: N-phenacylthiazolium bromide (PTB) decreases renal age levels and increases urinary age excretion, without ameliorating diabetic nephropathy in C57BL/6 mice. Am. Soc. Nephrol (2001): 641A.
   Google Scholar
• WOLFFENBUTTEL BH, BOULANGER CM, CRIJNS FR et al: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. (1998) 95:4630–4634.
   PubMed Web of Science ®Google Scholar
• ASIF M, EGAN J, VASAN S et al.: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. (2000) 97:2809–2813.
   PubMed Web of Science ®Google Scholar
• VAITKEVICIUS PV, LANE M, SPURGEON H et al.: A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. (2001) 98:1171–1175.
   PubMed Web of Science ®Google Scholar
• KASS DA, SHAPIRO EP, KAWAGUCHI M et al: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 104:1464–1470.
   PubMed Web of Science ®Google Scholar
• LEHMAN TD, ORTWERTH BJ: Inhibitors of advanced glycation end product-associated protein cross-linking. Biochim. Biophys. Acta (2001) 1535:110–119.
   PubMed Web of Science ®Google Scholar
• KHALIFAH RG, BAYNES JW, HUDSON BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. (1999) 257:251–258.
   PubMed Web of Science ®Google Scholar
• XIANG G, SCHINZEL R, SIMM A et al.: Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1. Nephrol Dial. Transplant. (2001) 16:1562–1569.
   PubMed Web of Science ®Google Scholar
• PARK KL, RAMOW KG, LEE KJ et al: Suppression of accelerated diabetic altherosclerosis by the soluble receptor for advanced glycation end-products. Nat. Med. (1998) 4:1025–1031.
   PubMed Web of Science ®Google Scholar